logo
Skin swabs may help detect Parkinson's years before symptoms appear

Skin swabs may help detect Parkinson's years before symptoms appear

There is currently no cure for Parkinson's disease, nor are there specific tests for early diagnosis. A new study has identified a way to detect the condition before symptoms appear through the use of skin swabs via sebum and smell. The swabs could offer a noninvasive way to help diagnose Parkinson's disease in people who have not yet developed symptoms. According to the Parkinson's Foundation, more than 10 million people around the world are living with Parkinson's disease — a neurological disease that negatively impacts a person's movement and speech abilities.There is currently no cure for Parkinson's disease. Although right now there are no specific tests to help diagnose the condition, identifying warning signs of Parkinson's disease as early as possible is critical in helping to slow disease progression. 'Current clinical diagnosis is too late as disease has progressed a lot,' Drupad K. Trivedi, PhD, lecturer in analytical and measurement science at the University of Manchester, told Medical News Today. Trivedi is the corresponding author of a new study recently published in the journal npj Parkinson's Disease that has identified a way to detect the condition before symptoms appear through the use of skin swabs. 'Smelling' signs of Parkinson's diseaseFor this study, scientists focused on testing study participants by using skin swabs of their sebum — an oily substance naturally produced by the skin's sebaceous glands.Through the skin swabs, Trivedi said they were able to detect volatile organic compounds (VOCs) in the sebum. Different VOCs have a distinct smell, which is what helps make each person's body odor unique. 'We have found a few compounds that are expressed differently in people with Parkinson's disease compared to healthy controls as well as those who had REM sleep behavior disorder. A test that is a simple skin swab can potentially be the first test to detect Parkinson's before all the clinical signs start appearing.' — Drupad K. Trivedi, PhDThis study is an extension of two previous studies conducted by Trivedi and his team. The first study in March 2019 identified the presence of VOC biomarkers in the sebum of people with Parkinson's disease that also has a distinct smell. A second study in February 2021 that found a differential VOC profile between participants with Parkinson's disease and controls when analyzing their sebum. All of this research was reportedly inspired by Joy Milne, a research associate at the University of Manchester, who has a condition called hyperosmia, giving her an extremely strong sense of smell. In 2015, it was reported that Milne was able to 'smell' Parkinson's disease on her husband about six years before he received his diagnosis.The concept of 'smelling' Parkinson's disease was further validated in a study recently published in the Journal of Parkinson's Disease — for which Trivedi was also part of the research team — that found trained dogs could detect an odor on skin swabs to detect Parkinson's disease. Sebum compound levels may indicate Parkinson's diseaseResearchers recruited 83 study participants. Of this number, 46 had a Parkinson's disease diagnosis, 28 were healthy controls, and nine had isolated REM Sleep Behavior Disorder (iRBD), which is considered to be an early warning sign of Parkinson's disease. Upon analysis, Trivedi and his team found that 55 significant features in the sebum that varied between the groups, and those with iRBD had levels in between those with Parkinson's disease and the healthy controls.'There were 55 features that showed levels for iRBD between healthy and Parkinson's disease,' Trivedi detailed. 'iRBD is one of the prodromal symptoms of Parkinson's disease. This means a good proportion of individuals suffering from iRBD may develop Parkinson's disease in the next decade or more. The intermediate level indicates a progression from control to iRDB to Parkinson's disease.' 'By early detection, we will be able to triage and offer advanced clinical tests, specialist support for confirmatory diagnosis without relying on physical symptoms to appear,' he continued. 'It also creates a potential to develop disease-modifying therapies in the future.' 'Next steps are to quantify these observed compounds in Parkinson's disease and iRBD, and also validate these findings in a long-term prospective study of [a] bigger iRBD cohort,' Trivedi added. Sebum VOCs may also help map Parkinson's progressionAdditionally, Trivedi collected sebum samples from people with Parkinson's disease over a three-year period. From these samples, he was able to find sebum compound patterns that suggest this method may also be used to map disease progression. 'This indicates that molecules we see on (the) skin surface may indicate progression of Parkinson's disease — it is a progressive disease with no cure,' he explained. 'A sudden, rapid progression could be monitored in future using such markers on [the] skin surface. There is also a potential to monitor [the] efficacy of treatment by such an approach.'Possible noninvasive tool for diagnosing presymptomatic Parkinson'sMNT also spoke with Rocco DiPaola, MD, a neurologist and movement disorder specialist at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center in New Jersey, about this study. DiPaola commented that this study's results would offer a noninvasive tool for potentially diagnosing presymptomatic Parkinson's disease. 'While there are currently no treatments that prevent or slow the progression of disease, as these treatments become available, it will be important to identify those at risk prior to symptom onset,' he continued. 'Further studies on a larger scale to further determine validity of results as well as a means to have this available as a standardized test. Although not specific to this study, it would be important to continue to find ways to diagnose Parkinson's disease prior to symptom onset.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

time6 minutes ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

Reuters

time2 hours ago

  • Reuters

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.

Grandmother died of sepsis after being misdiagnosed with stomach complaint
Grandmother died of sepsis after being misdiagnosed with stomach complaint

Telegraph

time3 hours ago

  • Telegraph

Grandmother died of sepsis after being misdiagnosed with stomach complaint

A grandmother died of sepsis after doctors failed to recognise signs of a urinary tract obstruction, a coroner has found. Suzanne Edwards, 71, of Leighton Buzzard, Bedfordshire, visited her GP on Nov 29 2024 with abdominal pain and vomiting but despite urgent blood and urine tests she was not sent to hospital. Later that day her symptoms worsened and she went to A&E at Milton Keynes University Hospital, Bucks. Her test results were indicative of systemic inflammation and dehydration but she was diagnosed with gastroenteritis and discharged. Her condition deteriorated further and the following day her family called NHS 111. She was directed to an urgent care centre and transferred to Bedford Hospital where clinicians identified a 7mm stone in her urinary tract and sepsis. She underwent emergency surgery but died later on the evening of Dec 1 from septic shock. 'Heart of our family' Stacey Edwards, her daughter, said: 'My mum was the heart of our family – full of warmth, compassion and humour. 'It's devastating to know that her death may have been avoided if the signs of sepsis had been recognised sooner.' Her family described her as 'an unbelievably kind and caring woman with a wicked sense of humour and fun'. She leaves behind husband Terence, two children and two granddaughters. Stacey said: 'When she visited her GP she was so unwell she used a wheelchair. 'After she was taken to A&E we were told it was likely gastroenteritis. She was given IV fluids and pain relief but she was still in pain and struggling. 'There was very little communication from doctors and when she was discharged we were simply told to come back if symptoms returned. 'At home, things got worse. But because she'd been examined by medical professionals we thought she just needed time to recover. 'The call we received later that evening asking us to come in urgently is something we'll never forget. 'Neither is watching her suffer in those final days.' Jewellery went missing Soon after her death Mrs Edwards' family realised her jewellery worth thousands of pounds – three necklaces and four bracelets – were missing. Stacey said: 'Mum never took off her jewellery. 'It is heartbreaking to think someone may have taken advantage of such a tragic situation.' Bedfordshire Hospitals NHS Foundation Trust launched a full investigation and search at the time but the items were never found. Tom Osborne, the senior coroner for Milton Keynes, recorded a narrative verdict saying there was a failure to recognise the signs of a urinary tract obstruction, leading to missed opportunities to treat Mrs Edwards before sepsis developed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store